Quantitative Structure-Activity Relationship Study on Pyrrolotriazine Derivatives as Met Kinase Inhibitors

被引:0
作者
Sharma, B. K. [1 ]
Yashwant [1 ]
Srivastava, B. [1 ]
机构
[1] SK Govt Coll, Dept Chem, Sikar 332001, India
关键词
QSAR; Pyrrolotriazine derivatives; Met kinase inhibitory activity; Combinatorial protocol in multiple linear regression; HEPATOCYTE GROWTH-FACTOR; C-MET; VARIABLE SELECTION; PROSTATE-CANCER; RECEPTOR; QSAR; IDENTIFICATION;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Met kinase inhibitory activity of pyrrolotriazine derivatives has been quantitatively analyzed in terms of Dragon descriptors using combinatorial protocol in multiple linear regression (CP-MLR). The study has provided a rational approach for the development of new pyrrolotriazine derivatives as Met kinase inhibitors. The descriptors identified in CP-MLR analysis have highlighted the role of atomic Sanderson's electronegativity in modified Burden eigen value (BELe4) and in respective lag of 2D-autocorrelation (GATS7e), 9th order self-returning walk count (SRW09), structural information content of 4th order neighbourhood symmetry (SIC4) and aromatic ratio (ARR) to explain the Met kinase inhibitory activity of pyrrolotriazine derivatives. Certain structural fragments (C-005 and N-069) and number of five membered rings (TIROS) in molecular structures have also shown prevalence to optimize the Met kinase inhibitory activity of pyrrolotriazine derivatives. These guidelines may be used to develop new Met kinase inhibitors based on pyrrolotriazine scaffold.
引用
收藏
页码:8231 / 8245
页数:15
相关论文
共 27 条
[1]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[2]  
Akaike H., 1973, 2 INT S INFORM THEOR, P267
[3]  
[Anonymous], 102 STANF U LAB COMP
[4]  
[Anonymous], CHEMDRAW ULTR 6 0 CH
[5]  
[Anonymous], DRAGON SOFTWARE VERS
[6]   Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor [J].
Bhide, RS ;
Cai, ZW ;
Zhang, YZ ;
Qian, LG ;
Wei, D ;
Barbosa, S ;
Lombardo, LJ ;
Borzilleri, RM ;
Zheng, XP ;
Wu, LI ;
Barrish, JC ;
Kim, SH ;
Leavitt, K ;
Mathur, A ;
Leith, L ;
Chao, S ;
Wautlet, B ;
Mortillo, S ;
Jeyaseelan, R ;
Kukral, D ;
Hunt, JT ;
Kamath, A ;
Fura, A ;
Vyas, V ;
Marathe, P ;
D'Arienzo, C ;
Derbin, G ;
Fargnoli, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (07) :2143-2146
[7]   c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention [J].
Christensen, JG ;
Burrows, J ;
Salgia, R .
CANCER LETTERS, 2005, 225 (01) :1-26
[8]   MOLECULAR-CLONING OF A NEW TRANSFORMING GENE FROM A CHEMICALLY TRANSFORMED HUMAN CELL-LINE [J].
COOPER, CS ;
PARK, M ;
BLAIR, DG ;
TAINSKY, MA ;
HUEBNER, K ;
CROCE, CM ;
VANDEWOUDE, GF .
NATURE, 1984, 311 (5981) :29-33
[9]  
GAVAI AV, 2006, Patent No. 7064203
[10]  
GAVAI AV, 2007, 233 NAT M AM CHEM SO